Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Accumulated Expenses for 9 consecutive years, with $52.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 10.06% year-over-year to $52.3 million, compared with a TTM value of $52.3 million through Sep 2025, up 10.06%, and an annual FY2024 reading of $52.3 million, up 32.07% over the prior year.
  • Accumulated Expenses was $52.3 million for Q3 2025 at Autolus Therapeutics, up from $51.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $52.3 million in Q4 2024 and bottomed at $23.7 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $42.0 million, with a median of $40.8 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses fell 14.81% in 2021, then soared 72.38% in 2022.
  • Year by year, Accumulated Expenses stood at $23.7 million in 2021, then skyrocketed by 72.38% to $40.8 million in 2022, then dropped by 2.98% to $39.6 million in 2023, then skyrocketed by 32.07% to $52.3 million in 2024, then dropped by 0.02% to $52.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for AUTL at $52.3 million in Q3 2025, $51.4 million in Q2 2025, and $49.7 million in Q1 2025.